Sanofi India Ltd Q1 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tew5foz33oh5mj2lb6ulcmvp.pdf

Key Takeaways


Diabetes Franchise: The Growth Engine

Deepak Arora: "I am very, very excited and delighted to share the domestic results of quarter 2 of 2026... As promised last time, we will be investing ourselves into making sure that we optimize and maximize diabetes business unit, growing by double-digit and bring it above market growth. And here we are."

Partnership Business: Below Expectations, Reorganization Underway

Deepak Arora: "as we move couple of quarters, we should be getting closer to the market growth if not on the market growth, knowing that this is generic market, everyone is playing very competitive"

Financials: Underlying Strength Beneath the One-Off Noise

Rachid Ayari: "...yesterday we were in the Board Meeting, and we try to eliminate all one-off, and you find out that, you know, if you take all the one-off, you know, the top line will be positive. And if you take the bottom line, you know, the profit before tax and exceptional items, we have a kind of, you know, high-digit growth if we exclude, all the one-off from last year and all what is related to this transition period with the partners."

Export Business: Australia Headwinds, Goa Specialization Offsets


Competitive Landscape & Innovation Pipeline

Deepak Arora: "I think it's too early to comment on if there's a major impact which will happen, but I think the market will open up, especially on the patients at the time of initiations, which were not getting onto the insulin therapy because of the daily injection"

Capital Allocation: Cash-Rich, Return-Cautious

Rachid Ayari: "we are expecting that we will be minimum at last year payout, but then there are decisions and discussion that will be done at the Board and the final decision and the proposal will be from the Board. So, today, we cannot commit."

Guidance & Commitments

CommitmentSpecificsTimeline
Diabetes franchise growthContinue double-digit growth above market; "not leaving any grounds to make sure that what we have seen in the first half to repeat it in second half"H2 FY27
Partnership business growthNot expected to reach industry growth in FY26; FY27 being evaluated for reaching industry growthFY26 / FY27
Partnership trajectory"As we move couple of quarters, we should be getting closer to the market growth if not on the market growth"Next few quarters
Opex trendOpex reduction to continue without impacting top lineOngoing
Dividend payoutMinimum at last year's payout level; final decision by BoardFY26
Buyback"As today, it's not in the strategy"No timeline
Awiqli impact assessment"We have to wait for a quarter to really see the momentum"Q3 FY26

Key Metrics

MetricQ1 FY27
Revenue (total income)+7% YoY
Domestic sales growth+8% YoY
Export sales growth-2% YoY
Diabetes business growth~14% YoY
Diabetes business H1 growth+17%
Partnership business growth+2% YoY
Profit before tax and exceptional items₹112 cr, +19% YoY from ₹94 cr
PBT as percentage of net sales27%, up from 24% YoY
Operating expenses-5% YoY
Cash position growth+34%
Basal analog market share (value)58%
Basal analog market share (volume)~61%
Soliqua growth+16% QoQ
Toujeo market share growth (value)+11%
Public sector growth (Toujeo and Soliqua)~70%